SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.98+1.1%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: software salesperson1/12/2023 11:27:13 AM
1 Recommendation

Recommended By
sjemmeri

  Read Replies (1) of 52153
 
cnn's report issued yesterday was one of the worst pieces written about the bivalent booster - - shoddy and inaccurate. it did correctly address the lack of transparency from moderna about the infections it caused.

from bob wachter, uscf:

important thread:
@EricTopol
was a bit skeptical about the bivalent when it rolled out. His detailed review of emerging lab & clinical data has convinced him that it truly represents a life-saving advance. Tragic that its under-use will lead to thousands of preventable deaths


yesterday eric topol issued a new substack that addressed these errors. among the conclusions are these excerpts:





You may recall that I was a skeptic about the bivalent BA.5 vaccine when the FDA gave it the OK to roll out in September without any human data. At the very least, I had hoped there would be lab studies to confirm a strong immune response to this variant, and that it was superior to the original (monovalent) booster that was directed to the ancestral (Wuhan) strain. But we now have extensive data that is quite encouraging—better and broader than expected— that I’m going to briefly review here.

Among more than 700,000 participants age 65 and older, who either had the bivalent or did not, there was a n 81% reduction of Covid hospitalizations (Figure below) and an 86% reduction of deaths. - - in israel

On December 30, 2022 the CDC issued 2 Morbidity and Mortality weekly reports (MMWR) on the initial bivalent booster vaccine effectiveness. Here are the data for a ge 65 and older, showing marked protection vs. hospitalization ranging from 73 to 84%, comparing not only to those unvaccinated but also those individuals who had been vaccinated and boosted. A second report was for all adults age 18 and up, showing bivalent booster 38 to 57% effectiveness vs hospitalization, which is consistent, but of lower magnitude than for seniors.



conclusion: getting the bivalent booster is the right choice.

erictopol.substack.com


Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News